MARTIGNONI, EMILIA SILVANA
 Distribuzione geografica
Continente #
NA - Nord America 5.831
EU - Europa 3.466
AS - Asia 1.504
SA - Sud America 149
AF - Africa 7
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 10.970
Nazione #
US - Stati Uniti d'America 5.800
IT - Italia 1.727
UA - Ucraina 617
SG - Singapore 591
SE - Svezia 288
TR - Turchia 244
VN - Vietnam 205
IE - Irlanda 193
HK - Hong Kong 192
CN - Cina 178
FI - Finlandia 172
GB - Regno Unito 162
BR - Brasile 130
DE - Germania 121
RU - Federazione Russa 84
IN - India 34
FR - Francia 32
BE - Belgio 21
CA - Canada 19
JP - Giappone 17
BD - Bangladesh 14
AT - Austria 8
ES - Italia 8
NL - Olanda 8
EU - Europa 6
MX - Messico 6
AR - Argentina 5
PL - Polonia 5
BG - Bulgaria 4
ID - Indonesia 4
NZ - Nuova Zelanda 4
AU - Australia 3
CL - Cile 3
CO - Colombia 3
IQ - Iraq 3
LT - Lituania 3
TH - Thailandia 3
VE - Venezuela 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BB - Barbados 2
DK - Danimarca 2
EC - Ecuador 2
HR - Croazia 2
IL - Israele 2
JO - Giordania 2
MA - Marocco 2
MY - Malesia 2
PK - Pakistan 2
PY - Paraguay 2
SA - Arabia Saudita 2
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GL - Groenlandia 1
GR - Grecia 1
HN - Honduras 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
PE - Perù 1
QA - Qatar 1
RO - Romania 1
SV - El Salvador 1
TN - Tunisia 1
UZ - Uzbekistan 1
Totale 10.970
Città #
Milan 1.301
Fairfield 795
Chandler 587
Jacksonville 463
Woodbridge 442
Ashburn 396
Seattle 371
Singapore 333
Houston 324
Wilmington 302
Ann Arbor 253
Cambridge 250
Dublin 192
Hong Kong 191
Dallas 163
Princeton 154
Izmir 145
Nyköping 144
Boardman 104
Chicago 88
Dong Ket 88
San Mateo 77
Como 70
Rome 69
The Dalles 63
Dearborn 60
Beijing 44
San Diego 43
Ogden 33
Philadelphia 30
Los Angeles 26
Norwalk 20
Brussels 19
Santa Clara 19
Düsseldorf 18
Pune 17
São Paulo 17
Hanoi 15
Ho Chi Minh City 15
Munich 14
New York 14
Tokyo 14
Edinburgh 13
London 12
Turku 12
Atlanta 11
Verona 11
Kunming 9
Nanjing 8
San Francisco 8
Hefei 7
Nanchang 7
Auburn Hills 6
Brasília 6
Helsinki 6
Montreal 6
Orem 6
Stockholm 6
Amsterdam 5
Brooklyn 5
Guangzhou 5
Toronto 5
Dhaka 4
Fuzhou 4
Jinan 4
Rio de Janeiro 4
Belo Horizonte 3
Boston 3
Charlotte 3
Chengdu 3
Chongqing 3
Columbus 3
Council Bluffs 3
Curitiba 3
Fayetteville 3
Frankfurt am Main 3
Johannesburg 3
Kocaeli 3
Madrid 3
Miami 3
Nuremberg 3
Poplar 3
Porto Alegre 3
Redwood City 3
Sofia 3
Thiene 3
Vienna 3
Washington 3
Amman 2
Annapolis 2
Auckland 2
Bangkok 2
Barra Mansa 2
Bauru 2
Bogotá 2
Bologna 2
Brisbane 2
Campinas 2
Carapicuíba 2
Casablanca 2
Totale 8.043
Nome #
Calcium homeostasis is dysregulated in parkinsonian patients with l-DOPA-induced dyskinesias 216
5-hydroxytryptamine1B receptor and triptan response in migraine, lack of association with common polymorphisms 197
Changes of opioid modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual syndrome. 187
CARDIOVASCULAR AUTONOMIC MODULATION AND ACTIVITY OF CAROTID BARORECEPTORS AT ALTITUDE. 177
Disordered pupil reactivity in Parkinson's disease. 176
Changes of neuroendocrine axes in patients with menstrual migraine. 174
Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. 171
Autonomic regulation of heart rate and peripheral circulation: comparison of high altitude and sea level residents. 169
Stimulation of corticotrophin-releasing hormone release by the obese (ob) gene product, leptin, from hypothalamic explants. 167
BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease 167
A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. 166
The brain as a target for adrenocortical steroids: cognitive implications. 162
Changes in nociceptive flexion reflex threshold across the menstrual cycle in healthy women. 162
"Off" painful dystonia in Parkinson's disease treated with botulinum toxin. 161
The association of menstrual migraine with the premenstrual syndrome. 161
Combined response of plasma and platelet catecholamines to different types of short-term stress. 160
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study.The influence of age. 158
Neuroendocrine changes in luteal function in patients with premenstrual syndrome. 158
Psychometric properties of the Unified Parkinson's Disease Rating Scale and of the Short Parkinson's Evaluation Scale. 157
Migraine without aura and reproductive life events: a clinical epidemiological study in 1300 women. 157
An assessment of hypothalamo-pituitary-adrenal axis functioning in non-depressed, early abstinent alcoholics. 156
High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. 156
Is seborrhea a sign of autonomic impairment in Parkinson's disease? 153
Pituitary-adrenal responses to dexamethasone and CRH administration in patients with untreated Parkinson's disease. 152
A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. 152
Platelet catecholamines in cluster headache. 152
Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA. 152
Determination of hydroxyl free radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. 151
Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. 151
Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. 151
Effects of etoperidone on sympathetic and pituitary-adrenal responses to diverse stressors in humans. 150
Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. 149
Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl. 149
Functional changes of the basal ganglia circuitry in Parkinson's disease. 149
Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo. 148
The role of language areas in motor control dysfunction in Parkinson's disease. 147
Nocturnal sleep in multisystem atrophy with autonomic failure: polygraphic findings in ten patients. 147
Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psychosom Med. 2000 May-Jun;62(3):386-93. 147
Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. 146
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson’s disease. The effect of dopaminergic treatment 146
Non-hormonal therapy of premenstrual syndrome. 145
Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus. 144
Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. 143
Changes in motoneuron excitability of masseter muscle following exteroceptive stimuli in Parkinson's disease. 142
Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients 141
Interobserver reliability between neurologists in training of Parkinson's disease rating scales. A multicenter study. 140
Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease 140
Sleep attacks in Parkinson's disease: a clinical and polysomnographic study. 138
Motor complications of Parkinson's disease. 137
LISURIDE PLUS SELEGILINE IN THE TREATMENT OF EARLY PARKINSON'S DISEASE. 136
Parkinson's disease and reproductive life events. 136
Premenstrual dysphoric disorder and eating disorders. 135
The influence of gender in the evaluation of platelet and plasma catecholamines. 134
Medical healthcare use in Parkinson’s disease: survey in a cohort of ambulatory patients in Italy. 134
Pergolide compared with bromocriptine in Parkinson's disease: a multicenter,crossover, controlled study. 132
Expression polymorphism of the blood-brain barrier component P-glycoprotein(MDR1) in relation to Parkinson's disease. 131
Hashimoto's thyroiditis in association with Tolosa Hunt syndrome: a case report. 130
Active music therapy and Parkinson's disease: methods. 129
Electrophysiological study on jaw-opening reflex recorded from digastric muscle in Parkinson's disease and primary cranial dystonias. 128
The autonomic nervous system and hypoxia: mountain medicine. 125
Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease. 125
Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation. 125
CARDIOPRESSOR EFFECTS OF SHORT-TERM TREATMENT WITH CABERGOLINE IN L-DOPA STABLE RESPONDER PARKINSONIAN PATIENTS: RELEVANCE OF POSTPRANDIAL HYPOTENSION. 121
Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol. 2000 Sep;62(1):63-88. 120
ALTITUDE, EXERCISE, AND MOUNTAIN MEDICINE: LESSONS FROM THE FIELD. 120
Autonomic disorders in Parkinson's disease. 115
Terguride in stable Parkinson's disease. 114
LISURIDE AND BROMOCRYPTINE IN L-DOPA STABLE-RESPONDER PARKINSONIAN PATIENTS: A COMPARATIVE, DOUBLE-BLIND EVALUATION OF CARDIOPRESSOR AND NEUROCHEMICAL EFFECTS. 111
The effects of physical exercise at high altitude on adrenocortical function in humans. 111
Gene-environment interaction in parkinson's disease. The case of CYP2D6 gene polymorphism. 108
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease 106
Reproductive life milestones in women with Parkinson's disease. 105
Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial. 102
Further characterization of autonomic involvement in multiple system atrophy: a pupillometric study. 96
Parkinson's Disease Comorbidity Study Group. Comorbid disorders and hospitalisation in Parkinson's disease: a prospective study. 96
COMT inhibition and safety. 95
Evidence of alpha-N-acetyl beta-endorphin in human cerebrospinal fluid. 88
Totale 10.985
Categoria #
all - tutte 38.026
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.026


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021805 0 0 0 0 0 145 49 101 186 49 109 166
2021/2022824 93 66 80 112 12 46 28 38 30 116 62 141
2022/20231.405 104 89 219 128 93 302 0 172 165 46 59 28
2023/20241.987 342 358 334 355 361 88 6 69 47 14 2 11
2024/20251.019 2 31 245 31 13 67 11 68 130 61 79 281
2025/2026934 123 100 111 218 287 95 0 0 0 0 0 0
Totale 10.985